Abstract:Background: The subcutaneous ICD (S-ICD™) is an important advance in device therapy for the prevention of sudden cardiac death (SCD). Although current guidelines recommend S-ICD™ use, long-term data are still limited, especially in subgroups. Among several cardiac diseases that prone to SCD, coronary artery disease (CAD) carries several peculiarities that may hamper S-ICD™ therapy in this cohort. CAD can lead to an ischemic cardiomyopathy (ICM) with a reduced left-ventricular ejection fraction (LVEF) and bundle branch blocks, which can be difficult for ICD sensing and discrimination of arrhythmia. CAD is mainly driven by risk factors such as diabetes mellitus, which put these patients at an elevated risk for infectious complications of cardiac devices. Furthermore, in ICM myocardial scars are frequent and are a potential substrate for ventricular tachycardia, which may be accessible for antitachycardia pacing. At the moment, it remains unclear if there is a value of S-ICD™ therapy in this subgroup. Therefore, this study analysed patients with CAD. Materials and methods: All S-ICD™ patients with CAD as the main indication for ICD implantation (n = 45 patients) in our large-scaled single-center S-ICD™ registry (n = 249 patients) were included in this study. Baseline characteristics, appropriate and inappropriate shocks, and complications were documented in a mean follow-up of 22.5 ± 8.3 months. Results: Primary prevention of SCD was the indication for implantation of an S-ICD™ in 28 patients (62%). Of all 45 patients with an overall mean age of 58.1 ± 11.4 years, 40 were male (88%). The mean LVEF was 37.7 ± 12.6%. Three episodes of ventricular arrhythmia (one monomorphic, one polymorphic, one ventricular fibrillation) were adequately terminated in three patients (7%). In only one patient, oversensing resulting in an inappropriate shock was observed, which could be managed by changing the sensing vector. 15 of the examined 45 patients previously had a transvenous ICD, which was explanted due to system-related infections. In only two patients, S-ICD™ was changed to transvenous ICD because of the need of antibradycardia stimulation. There were no S-ICD™ system-related infections. Conclusion: The S-ICD™ seems to be a valuable option for the prevention of SCD in CAD patients. Patients with systemic infections of a transvenous ICD and, therefore, a need for an alternative might benefit from the absence of intracardiac leads as the S-ICD™ is safe and works flawlessly in these patients. Inadequate shock delivery was very rare, while every episode of ventricular arrhythmia was terminated by the first shock.

Process mapping strategies to prevent subcutaneous implantable cardioverter-defibrillator infections

Measures to Prevent Infection in Cardiac Implantable Electronic Device Replacements or Upgrades

Infection in patients with subcutaneous implantable cardioverter-defibrillator: Results of the S-ICD Post Approval Study

Prevention and Management of Cardiac Implantable Electronic Device Infections: State-of-the-Art and Future Directions

Update on cardiovascular implantable electronic device infections and their management: a scientific statement from the American Heart Association

Infective Endocarditis Involving Implanted Cardiac Electronic Devices: JACC Focus Seminar 1/4

Burden of disease and costs of infections associated with cardiac implantable electronic devices

An Approach to Cardiac Implantable Electronic Device Pocket Infections: From Prevention to Diagnosis and Management

Contemporary Management of Cardiac Implantable Electronic Device Infection: The American College of Cardiology COGNITO Survey

Prevention and Risk Assessment of Cardiac Device Infections in Clinical Practice

Feasibility of entirely subcutaneous ICD™ systems in patients with coronary artery disease

Infection management in the extravascular implantable cardioverter defibrillator: experience from the EV ICD Pivotal study

New advances in management and treatment of cardiac implantable electronic devices infections

Incidence and Predictors of Infections and All-Cause Death in Patients with Cardiac Implantable Electronic Devices: The Italian Nationwide RI-AIAC Registry

Cardiovascular Implantable Electronic Device Infections: A Contemporary Review

Antibiotic eluting envelopes: evidence, technology, and defining high-risk populations

Decision-making regarding subcutaneous implantable cardioverter defibrillator as primary prevention in patients with low ejection fraction

Evidence-Based Strategies to Promote Long-Term Cardiac Implant Site Health: Review of the Literature

Antibiotic Prophylaxis and Treatment for Cardiac Device Infections

Cardiovascular implantable electronic device infections due to enterococcal species: Clinical features, management, and outcomes

Impact of Cardiac Implantable Electronic Device Infection: A Clinical and Economic Analysis of the WRAP-IT Trial